Denosumab Efficacy and Safety

Clinical Efficacy and Safety Considerations

• The ABCSG-18 trial showed that denosumab significantly delayed time to occurrence of clinical fractures (HR, 0.5; 95% CI, 0.39 to 0.65; P < .001) 1
• Monitor for hypocalcemia, which is a listed contraindication 2
• When denosumab is discontinued, there may be an increased risk of vertebral fractures, and the European Calcified Tissue Society suggests using a bisphosphonate to reduce fracture risk 3